Belite Bio, Inc (BLTE)

Price$186.62Cached quoteAs of 2026-09-04 16:23 UTC

AI: Fair-priced

Price checkThe valuation already discounts meaningful success, but strong Stargardt sales and GA optionality can plausibly support it.

Belite Bio, Inc. trades on the Nasdaq Capital Market as BLTE, with each ADS representing one ordinary share. Using 40.27 million shares outstanding at June 30, the latest reliable quote implies an equity value of about $7.4 billion. Subtracting roughly $780 million of cash and U.S. Treasuries leaves about $6.6 billion being paid for the pipeline. That is demanding for a company with no product revenue, but not obviously excessive if tinlarebant wins approval, launches well, and geographic atrophy adds value.

Big pictureCash is unusually strong for a clinical biotech, while spending and share dilution are both rising.

Second-quarter 2026 net loss was $28.4 million, and first-half loss was $55.4 million. At June 30, cash plus Treasury securities totaled about $780 million, versus only $14.9 million of total liabilities, so leverage is not the main risk. Capital allocation is conservative today: liquidity is mostly held in cash and Treasuries while spending targets trials, manufacturing, regulatory work, and launch preparation. Financing has relied heavily on equity; ordinary shares outstanding rose from 39.34 million at year-end to 40.27 million by June 30, diluting each existing share’s ownership percentage.

Business strengthPhase 3 success and Priority Review strengthen the case, but the company remains concentrated in one lead asset.

DRAGON met its primary endpoint, and the FDA accepted tinlarebant’s Stargardt NDA with Priority Review and a February 12, 2027 action date. Belite is also running DRAGON II and the 530-patient PHOENIX Phase 3 trial in geographic atrophy, giving the same molecule a second, much larger potential market. Demand for a rare retinal therapy should be less tied to economic cycles than most businesses; the important cycle here is clinical and regulatory, where data, approval, reimbursement, safety, and launch execution can sharply change value.

What could change the storyApproval and strong uptake could justify more; slower adoption or regulatory setbacks would expose substantial downside.

Illustrative bull case: approval, 12,000 U.S. patients at a $150,000 annual net price, and valuing the product at five times annual sales imply about $9.0 billion of product value before cash or GA. Illustrative bear case: 4,000 patients at $75,000 and three times annual sales imply about $900 million before cash. These are assumptions, not guidance. Recent analyst models are more bullish: Mizuho cites $3.4 billion of risk-adjusted worldwide revenue, while Canaccord models roughly $6 billion of U.S. sales by 2033. Current valuation sits between weak and strong outcomes, supporting a Fair-priced verdict with wide uncertainty.

AI: News

Japan NDA submittedBelite filed tinlarebant for Stargardt disease in Japan under the Sakigake accelerated-review framework.

On September 8, 2026, Belite submitted an NDA to Japan’s Ministry of Health, Labour and Welfare for tinlarebant in Stargardt disease type 1. The application uses the Sakigake designation system, which is intended to speed consultation and review of innovative medicines. Approval is not guaranteed, but a Japanese filing broadens the commercial opportunity beyond the United States and provides another regulatory path for the company’s lead asset.

Q2 loss widensQuarterly losses widened as Belite increased research, manufacturing, professional services, and commercial-launch preparation spending.

On August 12, 2026, Belite reported a second-quarter net loss of $28.4 million, versus $16.3 million a year earlier, as operating expenses increased. Cash and cash equivalents were $279.9 million and U.S. Treasury investments were $500.1 million at June 30. The balance sheet therefore remains a major support while the company prepares for a possible launch and continues the DRAGON II and PHOENIX clinical programs.

FDA grants Priority ReviewThe FDA accepted tinlarebant’s Stargardt application for Priority Review, creating a defined near-term decision date.

On August 11, 2026, the FDA accepted Belite’s NDA and granted Priority Review, setting a February 12, 2027 PDUFA target date. PDUFA is the agency’s target date for acting on a drug application. If approved, tinlarebant would be the first approved treatment for Stargardt disease type 1. This shifts the investment story toward a near-term regulatory decision, while launch execution, reimbursement, manufacturing, and post-approval safety remain important risks.

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2020

2021

2022

2023

2024

2025

Free cash flow

2021

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2020

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021	2020
Revenue	$0	$0	$0	$0	—	—
Research & development	$45.4M	$29.9M	$24.8M	$8.9M	$7.4M	$3.7M
Operating expenses	$84.2M	$40.0M	$31.7M	$12.8M	$9.8M	$5.7M
Operating income	−$84.2M	−$40.0M	−$31.7M	−$12.8M	−$9.8M	−$5.7M
EBITDA	−$84.0M	−$39.8M	−$31.5M	−$12.8M	−$9.8M	−$5.7M
Net income	−$77.6M	−$36.1M	−$31.6M	−$12.6M	−$9.7M	−$5.8M
Basic EPSper basic share	-$2.31	-$1.18	-$1.19	-$0.63	-$1.01	-$0.65
Diluted EPSper diluted share	-$2.31	-$1.18	-$1.19	-$0.63	-$1.01	-$0.65

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

Reported holdings Number of shares

View holders

Top 20 reported holders of BLTE
Holder	Shares held
Darwin Global Management, Ltd.	3.08M
Paradigm Biocapital Advisors LP	1.23M
RTW INVESTMENTS, LP	715.33K
MILLENNIUM MANAGEMENT LLC	494.56K
MAVERICK CAPITAL LTD	396.31K
EVENTIDE ASSET MANAGEMENT, LLC	390.83K
DEERFIELD MANAGEMENT COMPANY, L.P.	357.2K
Holocene Advisors, LP	251.04K
Logos Global Management LP	250K
MORGAN STANLEY	235.07K
UBS Group AG	224.99K
CITADEL ADVISORS LLC	186.17K
GOLDMAN SACHS GROUP INC	166.19K
Affinity Asset Advisors, LLC	165K
MPM BIOIMPACT LLC	137.21K
BANK OF AMERICA CORP /DE/	124.78K
Patient Square Capital LP	110K
Duquesne Family Office LLC	106.1K
PRICE T ROWE ASSOCIATES INC /MD/	105.86K
JANE STREET GROUP, LLC	65.8K

Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)125$8.52M disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Jun 18, 2026Form 4	Scholl Hendrik PeterChief Medical Officer	SellAmerican depositary share · indirect	96	$147.11	$14.1K	15.0K
Jun 18, 2026Form 4	Scholl Hendrik PeterChief Medical Officer	SellAmerican depositary share · indirect	1.2K	$146.24	$175.3K	15.1K
Jun 18, 2026Form 4	Scholl Hendrik PeterChief Medical Officer	SellAmerican depositary share · indirect	4.9K	$145.43	$706.9K	16.3K
Jun 18, 2026Form 4	Scholl Hendrik PeterChief Medical Officer	SellAmerican depositary share · indirect	3.7K	$144.66	$542.2K	21.2K
Jun 18, 2026Form 4	Scholl Hendrik PeterChief Medical Officer	SellAmerican depositary share · indirect	96	$143.90	$13.8K	24.9K